Natera, Inc. v. CareDx, Inc. — Fed. Cir. (Nov 9, 2026)

No. 24-1894 Argued November 9, 2026 Published November 10, 2026

The Federal Circuit hears a patent battle between Natera and Care D X over blood tests used to monitor organ transplants. Natera accused Care D X of using its patented methods for measuring small amounts of one person's DNA mixed with another's. A jury found one Natera patent infringed and awarded about ninety-six million dollars in damages. The judge later invalidated the asserted claims in both patents at trial because their written descriptions did not adequately disclose the claimed inventions. Natera will argue that the jury had enough evidence to find the inventions disclosed; Care D X will argue that listing separate pieces does not describe the combined method. Two different questions will recur: whether the patent described the claimed combination, and whether DNA-analysis methods qualify for patent protection at all.

Natera, Inc. v. CareDx, Inc. (No. 24-1894) — U.S. Court of Appeals for the Federal Circuit, argued November 9, 2026.

Sources

Argument audio — official Federal Circuit recording, November 9, 2026; complete source with gentle volume balancing, no noise filtering or speech reconstruction:https://www.cafc.uscourts.gov/oral-arguments/24-1894_11092026.mp3

Prior case background and written-description ruling — District of Delaware memorandum opinion, February 24, 2025, Document 558, pages 1–21:https://www.govinfo.gov/content/pkg/USCOURTS-ded-1_20-cv-00038/pdf/USCOURTS-ded-1_20-cv-00038-3.pdf

Independent case-history and jury-award cross-check — Natera 2025 Form 10-K, Note 10, second CareDx patent case:https://www.sec.gov/Archives/edgar/data/1604821/000110465926020881/ntra-20251231x10k.htm

0:00Introduction